Health
In this fast-paced bull market, we're increasing our Club price targets on 4 stocks
It’s been hard to keep up. That’s the story of the big stock winners this year. They just keep winning and winning and winning. For analysts on Wall Street and here at the Club, it seems like some of these names are smashing through our six-to-nine-month price targets every few weeks. To that end, we’re […]
Read More
What Eli Lilly investors can learn from the slow launch of a competitor's drug
Club holding Eli Lilly is expecting to get approval for its Alzheimer’s treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. On its fourth-quarter earnings call Tuesday, rival drugmaker Biogen shared data that showed its therapy for the memory-robbing disease, Leqembi, is off to a slower-than-expected start. In […]
Read More
Jim Cramer praises GE following U.S. regulatory approval to develop nuclear fuel
CNBC’s Jim Cramer called out General Electric as a winner in the industrial sector for the strides it’s making in nuclear power. GE’s Verona Nuclear Fuel business said Wednesday it received approval from the U.S. Nuclear Regulatory Commission to manufacture, ship, and analyze the performance of higher enrichment fuel. These “regulatory milestones” will help the […]
Read More
Healthy Returns: Higher medical costs are pinching insurers
A UnitedHealth Group health insurance card is seen in a wallet, Oct.14, 2019. Lucy Nicholson | Reuters Good afternoon! Health insurers are feeling the squeeze as older patients head to the doctor more than expected. CVS, which owns health insurer Aetna, on Wednesday slashed its full-year profit outlook, citing the potential for higher medical costs to bite […]
Read More
Here's why we would be considering buying more Eli Lilly shares if they were down Tuesday
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. U.S. stocks tumbled Tuesday on hotter-than-expected retail inflation data. The surprise uptick in the January consumer price index sent bond yields higher and the Dow , the S & […]
Read More
Federal judge tosses lobbying group's lawsuit challenging Medicare drug price negotiations
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images A federal judge on Monday tossed a lawsuit brought by a major pharmaceutical industry lobbying group and two other organizations, which challenged […]
Read More
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer’s drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company’s biggest drug category. Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a […]
Read More
Wall Street changes its tune on this healthcare stock. Why we were always bullish
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. 1. U.S. stocks were modestly higher Monday as the market awaits key economic data. Traders will be mulling over the consumer price index Tuesday, retail sales Thursday, and the producer […]
Read More
Defense Secretary Lloyd Austin re-hospitalized for bladder issue
US Defense Secretary Lloyd Austin takes questions during a press conference at the Pentagon in Washington, DC, on February 1, 2024. Andrew Caballero-reynolds | Afp | Getty Images Defense Secretary Lloyd Austin was taken back to the hospital on Sunday afternoon for symptoms related to a possible bladder issue, the Pentagon announced. Austin is battling […]
Read More
Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters The insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly, have said […]
Read More